<DOC>
	<DOCNO>NCT00623194</DOCNO>
	<brief_summary>This trial conduct Europe . The aim research ass safety continuous treatment insulin detemir follow participation trial NN304-1689 ( NCT00435019 ) antibody development .</brief_summary>
	<brief_title>Safety Follow-up Children Adolescents With Type 1 Diabetes Treated With Insulin Detemir . An Extension Trial NN304-1689</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Informed Consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) . The parent legal representative subject must sign date Informed Consent Form . Finalised 52 week treatment insulin detemir trial NN3041689 . Fertile female ( girl first menstrual period ) must use adequate contraception ( barrier method , contraceptive pill intrauterine device ( IUD ) ) risk pregnancy opinion Investigator . For Denmark France contraceptive pill intrauterine device consider adequate contraceptive method . Significant concomitant disease endocrine , hepatic , renal , cardiac , respiratory , neurological , gastrointestinal , malignant pancreatic disease judge Investigator . Pregnant intention become pregnant . Previous participation trial ( defined enrolment ) .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>